Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
B 6.29 -5.98% -0.40
ANNX closed down 5.98 percent on Monday, March 18, 2024, on 1.87 times normal volume. The bulls were able to push the stock to a new 52-week high.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
MACD Bullish Signal Line Cross Bullish -5.98%
New 52 Week Closing High Bullish -5.98%
180 Bullish Setup Bullish Swing Setup -5.98%
Expansion Breakout Bullish Swing Setup -5.98%
Pocket Pivot Bullish Swing Setup -5.98%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 15 hours ago
Gap Up Closed about 20 hours ago
Gap Up Partially Closed about 20 hours ago
2x Volume Pace about 20 hours ago
1.5x Volume Pace about 20 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Annexon, Inc. Description

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Immune System Eye Monoclonal Antibody Antibody Ophthalmic Biomarkers Autoimmunity Platform Technology Degenerative Disease Neurodegenerative Disorders Complement System Intravitreal Administration

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.0
52 Week Low 1.57
Average Volume 1,348,294
200-Day Moving Average 3.39
50-Day Moving Average 4.98
20-Day Moving Average 5.40
10-Day Moving Average 5.39
Average True Range 0.69
RSI (14) 61.24
ADX 32.55
+DI 32.01
-DI 12.02
Chandelier Exit (Long, 3 ATRs) 4.93
Chandelier Exit (Short, 3 ATRs) 6.47
Upper Bollinger Bands 6.46
Lower Bollinger Band 4.35
Percent B (%b) 0.92
BandWidth 39.20
MACD Line 0.26
MACD Signal Line 0.17
MACD Histogram 0.0863
Fundamentals Value
Market Cap 492.34 Million
Num Shares 78.3 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -3.48
Price-to-Sales 0.00
Price-to-Book 2.72
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.51
Resistance 3 (R3) 7.61 7.30 7.30
Resistance 2 (R2) 7.30 6.99 7.25 7.23
Resistance 1 (R1) 6.80 6.80 6.65 6.70 7.17
Pivot Point 6.49 6.49 6.42 6.44 6.49
Support 1 (S1) 5.99 6.18 5.84 5.89 5.41
Support 2 (S2) 5.68 5.99 5.63 5.35
Support 3 (S3) 5.18 5.68 5.28
Support 4 (S4) 5.08